Eplontersen
Brand names: Wainua · Active ingredient: Eplontersen
In short: WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
What is Eplontersen used for?
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Eplontersen dosage
The recommended dosage of WAINUA is 45 mg administered by subcutaneous injection once monthly .
Missed Dose
Administer WAINUA as soon as possible after a missed dose. Resume dosing at monthly intervals from the date of the most recently administered dose.
Each autoinjector and prefilled syringe contains a single dose of WAINUA.
Prior to administration of the autoinjector or prefilled syringe:
•
Do not use if WAINUA has been dropped or damaged, appears to be tampered with, or if the expiration date has passed.
•
Remove WAINUA from the refrigerator 30 minutes prior to the injection to reach room temperature. Do not use other warming methods.
•
Visually inspect WAINUA before use. The solution should appear colorless to yellow. Do not use if cloudiness, particulate matter, or discoloration is observed.
To deliver a 45 mg dose of WAINUA, administer the entire contents of one autoinjector or prefilled syringe
, as a subcutaneous injection in the upper thigh or the abdomen. The back of the upper arm can also be used as an injection site if a healthcare provider or caregiver administers the injection. Do not inject WAINUA into the area 2 inches (5 cm) around the navel or into areas where the skin is red, warm, tender, bruised, scaly or hard. Rotate the injection site with each injection.
The autoinjector is intended for self-administration by patients or administration by caregivers.
Prior to initiation, train patients and/or caregivers on proper preparation and administration of WAINUA autoinjector
.
The prefilled syringe must be administered by a healthcare provider.
Refer to Figure 1 to identify the prefilled syringe components for use in the administration steps.
Do not remove the needle cover until you are ready to inject WAINUA. Do not touch the needle guard activation clips to prevent premature activation of the needle safety guard.
Figure 1: WAINUA Prefilled Syringe Components
Administration Steps
Step 1 Remove the prefilled syringe from its tray. Hold the syringe body and remove the needle cover by pulling straight off. Do not recap. If small air bubbles are present, do not expel them prior to administration.
Step 2 Choose an injection site (i.e., back of upper arm, upper thigh, or abdomen). Gently pinch the skin and insert the needle subcutaneously at approximately a 45° angle into the chosen injection site.
Step 3 Once the entire dose has been injected, the needle safety device will be triggered. As you let go of the plunger, the needle is automatically pulled from the skin, and into the device; the entire needle will be covered by the needle guard.
How to take Eplontersen — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
Recommended Vitamin A Supplementation
Inform patients that WAINUA treatment leads to a decrease in vitamin A levels measured in the serum. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness, dry eyes) and refer them to an ophthalmologist if they develop these symptoms .
Pregnancy
Instruct patients that if they are pregnant or plan to become pregnant while taking WAINUA they should inform their healthcare provider. Advise patients of the potential risk to the fetus, including that WAINUA treatment leads to a decrease in serum vitamin A levels .
Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
©AstraZeneca 2026
Warnings & precautions
Do not take this medicine if: None.
WAINUA treatment leads to a decrease in serum vitamin A levels [see Adverse Reactions (6.1), Use in Specific Populations (8.1), and Clinical Pharmacology (12.2)].
Supplementation at the recommended daily allowance of vitamin A is advised for patients taking WAINUA. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with WAINUA, as serum vitamin A levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness, dry eyes).
Eplontersen side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
•Reduced Serum Vitamin A Levels and Recommended Supplementation .
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of WAINUA cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In Study 1 , a total of 144 patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) were randomized to WAINUA and received at least one dose of WAINUA. Of these, 141 patients received at least 6 months of treatment and 107 patients received at least 12 months of treatment. The mean duration of treatment was 15 months (range: 1.9 to 19.4 months). The median patient age at baseline was 52 years and 69% of the patients were male. Seventy-eight percent of patients treated with WAINUA were White, 15% were Asian, 4% were Black, 2% were reported as other races, and <1% were multiple races. Fifty-nine percent of patients had the Val30Met variant in the transthyretin gene; the remaining patients had one of 19 other variants. At baseline, 80% of patients were in Stage 1 of the disease and 20% were in Stage 2 with a mean duration from polyneuropathy diagnosis of 47 months. The mean duration from onset of polyneuropathy symptoms was 68 months. …
About this medicine
Eplontersen is a transthyretin-directed antisense oligonucleotide (ASO), covalently linked to a ligand containing three N-acetyl galactosamine (GalNAc) residues to enable delivery of the ASO to hepatocytes.
WAINUA contains eplontersen sodium as the active ingredient. Eplontersen sodium is a white to yellow solid and it is freely soluble in water and in phosphate buffer. The molecular formula of eplontersen sodium is C296H417N77O156P20S13Na20 and the molecular weight is 9046.1 daltons. The chemical name of eplontersen sodium is DNA, d([2′-O-(2-methoxyethyl)]m5rU-sp-[2′-O-(2-methoxyethyl)]m5rC-[2′-O-(2-methoxyethyl)]m5rU-[2′-O-(2-methoxyethyl)]m5rU-[2′-O-(2-methoxyethyl)]rG-G-sp-T-sp-T-sp-A-sp-m5C-sp-A-sp-T-sp-G-sp-A-sp-A-sp-[2′-O-(2-methoxyethyl)]rA-[2′-O-(2-methoxyethyl)]m5rU-[2′-O-(2-methoxyethyl)]m5rC-sp-[2′-O-(2-methoxyethyl)]m5rC-sp-[2′-O-(2-methoxyethyl)]m5rC), 5′-[26-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[6-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]hexyl]amino]-3-oxopropoxy]methyl]-8,12,19-trioxo-16-oxa-7,13,20-triazahexacos-1-yl hydrogen …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d7dcb847-71dd-4fff-82d0-d43a465fc096. Read the full official label on DailyMed.